Renaissance Technologies LLC cut its position in LeMaitre Vascular Inc (NASDAQ:LMAT) by 37.8% during the fourth quarter, Holdings Channel reports. The fund owned 157,000 shares of the medical instruments supplier’s stock after selling 95,600 shares during the period. Renaissance Technologies LLC’s holdings in LeMaitre Vascular were worth $4,999,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of LMAT. Algert Global LLC boosted its stake in LeMaitre Vascular by 2.0% during the fourth quarter. Algert Global LLC now owns 86,858 shares of the medical instruments supplier’s stock worth $2,766,000 after buying an additional 1,673 shares during the last quarter. Rhumbline Advisers boosted its stake in LeMaitre Vascular by 3.7% during the fourth quarter. Rhumbline Advisers now owns 60,673 shares of the medical instruments supplier’s stock worth $1,932,000 after buying an additional 2,138 shares during the last quarter. Congress Asset Management Co. MA boosted its stake in LeMaitre Vascular by 6.5% during the fourth quarter. Congress Asset Management Co. MA now owns 42,898 shares of the medical instruments supplier’s stock worth $1,366,000 after buying an additional 2,611 shares during the last quarter. California Public Employees Retirement System boosted its stake in LeMaitre Vascular by 5.5% during the third quarter. California Public Employees Retirement System now owns 52,283 shares of the medical instruments supplier’s stock worth $1,956,000 after buying an additional 2,736 shares during the last quarter. Finally, Strs Ohio boosted its stake in LeMaitre Vascular by 16.6% during the fourth quarter. Strs Ohio now owns 22,500 shares of the medical instruments supplier’s stock worth $716,000 after buying an additional 3,200 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.
In other LeMaitre Vascular news, CEO George W. Lemaitre sold 42,036 shares of LeMaitre Vascular stock in a transaction on Monday, February 26th. The stock was sold at an average price of $35.68, for a total value of $1,499,844.48. Following the sale, the chief executive officer now owns 3,259,263 shares in the company, valued at $116,290,503.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman George W. Lemaitre sold 30,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $36.19, for a total value of $1,085,700.00. Following the completion of the sale, the chairman now owns 3,180,709 shares in the company, valued at approximately $115,109,858.71. The disclosure for this sale can be found here. Insiders sold 137,736 shares of company stock worth $4,866,186 in the last 90 days. Company insiders own 23.70% of the company’s stock.
NASDAQ LMAT opened at $40.90 on Tuesday. The firm has a market cap of $776.07, a price-to-earnings ratio of 47.56, a P/E/G ratio of 2.75 and a beta of 0.54. LeMaitre Vascular Inc has a fifty-two week low of $24.89 and a fifty-two week high of $41.09.
LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. LeMaitre Vascular had a return on equity of 16.93% and a net margin of 17.03%. The company had revenue of $26.15 million for the quarter, compared to the consensus estimate of $26.23 million. During the same quarter in the previous year, the business earned $0.13 earnings per share. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. equities analysts forecast that LeMaitre Vascular Inc will post 0.98 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, April 5th. Shareholders of record on Thursday, March 22nd were given a $0.07 dividend. The ex-dividend date of this dividend was Wednesday, March 21st. This represents a $0.28 dividend on an annualized basis and a yield of 0.68%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.06. LeMaitre Vascular’s payout ratio is currently 32.56%.
A number of equities analysts have weighed in on LMAT shares. BidaskClub lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, March 1st. Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Canaccord Genuity reissued a “hold” rating and set a $33.00 price objective on shares of LeMaitre Vascular in a research note on Friday, February 23rd. Finally, ValuEngine raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Wednesday, April 4th. Four research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $34.00.
ILLEGAL ACTIVITY NOTICE: “LeMaitre Vascular Inc (LMAT) Shares Sold by Renaissance Technologies LLC” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/17/lemaitre-vascular-inc-lmat-shares-sold-by-renaissance-technologies-llc.html.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.